Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06411288 · ClinicalTrials.gov registry record · Phase 3
Global Study of Del-desiran for the Treatment of DM1
A Phase 3 study of Myotonic Dystrophy and Myotonic Dystrophy 1, sponsored by Avidity Biosciences.
- Active
- Registry status
- Phase 3
- Development phase
- 159
- Enrollment target
- 20
- Study locations
NCT06411288: Active Phase 3 study of Myotonic Dystrophy and Myotonic Dystrophy 1, sponsored by Avidity Biosciences.
NCT06411288 is a Phase 3 study of Myotonic Dystrophy and Myotonic Dystrophy 1 that is active but no longer recruiting, run by Avidity Biosciences. The registered enrollment target is 159 participants, below the 838-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06411288, a Phase 3 study of Myotonic Dystrophy and Myotonic Dystrophy 1, is active but no longer recruiting, sponsored by Avidity Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 159 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Primary Outcome
video Hand Opening Time (vHOT)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AOC 1001 (del-desiran)
Study Locations (20)
Florida
- University of Florida - Gainesville
- University Research Center of South Florida - Tampa
North Carolina
- Duke University Medical Center - Durham
- Wake Forest - Winston-Salem
Ohio
- University of Cincinnati Gardner Neuroscience Institute - Cincinnati
- Ohio State University - Columbus
California
- Stanford University - Stanford
Colorado
- University of Colorado - Denver
Indiana
- Indiana University (IU) - Indianapolis
Kansas
- Kansas University Medical Center - Kansas City
Maryland
- Kennedy Krieger Institute - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2024-05-30 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
What the registry record for NCT06411288 still lists
NCT06411288 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 838-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (81% lower).
The record links to 10 conditions, with Myotonic Dystrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06411288 names 20 study sites across 17 states, led by Florida, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT06411288 about?
NCT06411288 is a clinical study titled "Global Study of Del-desiran for the Treatment of DM1". A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
What is the current status of trial NCT06411288?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 159 participants. The study started on 2024-05-30. Estimated completion is 2026-09.
What conditions does trial NCT06411288 study?
This clinical trial studies the following conditions: Myotonic Dystrophy, Myotonic Dystrophy 1, DM1, Myotonic Dystrophy Type 1 (DM1), Myotonic Muscular Dystrophy.
What interventions are being tested in trial NCT06411288?
The interventions under investigation include: Placebo (DRUG), AOC 1001 (del-desiran) (DRUG).
Who is sponsoring clinical trial NCT06411288?
This trial is sponsored by Avidity Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06411288 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06411288's enrollment target sits among peer trials
159 6th of 9 higher than 4 of 9 other Myotonic Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myotonic Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
RECRUITING · Phase 1
-
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
RECRUITING
-
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
RECRUITING
-
Extracellular RNA Biomarkers of Myotonic Dystrophy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI